Indiplon in the treatment of sleep disorders

Alan LankfordSleep Disorders Center of Georgia, Atlanta, GA, USAAbstract: Indiplon is a novel sedative-hypnotic recently approved for the treatment of insomnia. Like other non-benzodiazepine hypnotics, its mechanism of action is to modulate subunits, especially the alpha-1 subunit, of the GABA recep...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Alan Lankford
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2007
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/a6bad236a8e943d49d0ebc3f46934ee8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a6bad236a8e943d49d0ebc3f46934ee8
record_format	dspace
spelling	oai:doaj.org-article:a6bad236a8e943d49d0ebc3f46934ee82021-12-02T08:24:56ZIndiplon in the treatment of sleep disorders1176-63281178-2021https://doaj.org/article/a6bad236a8e943d49d0ebc3f46934ee82007-01-01T00:00:00Zhttp://www.dovepress.com/indiplon-in-the-treatment-of-sleep-disorders-a956https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Alan LankfordSleep Disorders Center of Georgia, Atlanta, GA, USAAbstract: Indiplon is a novel sedative-hypnotic recently approved for the treatment of insomnia. Like other non-benzodiazepine hypnotics, its mechanism of action is to modulate subunits, especially the alpha-1 subunit, of the GABA receptor complex in order to induce sedation. Indiplon was developed in two different formulations to address two different types of insomnia complaint: indiplon-IR (immediate release) was designed for sleep onset difficulties, while indiplon-MR (modified release) was developed for sleep maintenance insomnia. While there are currently few peer reviewed articles about indiplon clinical trial results, the early information that is available seems to indicate that both formulations have been well tolerated and have proven effective at improving both patient reported and objectively measured sleep parameters in both adult and elderly insomnia patients. In May 2006, the FDA indicated that indiplon-IR was approvable and plans are to resubmit the application in 2007. Indiplon-MR was unapprovable and may require further evaluation.Keywords: indiplon, insomnia, GABAA receptor, sedative, non-benzodiazepine Alan LankfordDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2007, Iss Issue 6, Pp 765-773 (2007)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Alan Lankford Indiplon in the treatment of sleep disorders
description	Alan LankfordSleep Disorders Center of Georgia, Atlanta, GA, USAAbstract: Indiplon is a novel sedative-hypnotic recently approved for the treatment of insomnia. Like other non-benzodiazepine hypnotics, its mechanism of action is to modulate subunits, especially the alpha-1 subunit, of the GABA receptor complex in order to induce sedation. Indiplon was developed in two different formulations to address two different types of insomnia complaint: indiplon-IR (immediate release) was designed for sleep onset difficulties, while indiplon-MR (modified release) was developed for sleep maintenance insomnia. While there are currently few peer reviewed articles about indiplon clinical trial results, the early information that is available seems to indicate that both formulations have been well tolerated and have proven effective at improving both patient reported and objectively measured sleep parameters in both adult and elderly insomnia patients. In May 2006, the FDA indicated that indiplon-IR was approvable and plans are to resubmit the application in 2007. Indiplon-MR was unapprovable and may require further evaluation.Keywords: indiplon, insomnia, GABAA receptor, sedative, non-benzodiazepine
format	article
author	Alan Lankford
author_facet	Alan Lankford
author_sort	Alan Lankford
title	Indiplon in the treatment of sleep disorders
title_short	Indiplon in the treatment of sleep disorders
title_full	Indiplon in the treatment of sleep disorders
title_fullStr	Indiplon in the treatment of sleep disorders
title_full_unstemmed	Indiplon in the treatment of sleep disorders
title_sort	indiplon in the treatment of sleep disorders
publisher	Dove Medical Press
publishDate	2007
url	https://doaj.org/article/a6bad236a8e943d49d0ebc3f46934ee8
work_keys_str_mv	AT alanlankford indiploninthetreatmentofsleepdisorders
_version_	1718398559389220864

Indiplon in the treatment of sleep disorders

Ejemplares similares